Kadimastem
TASE:KDSTNess Ziona, Israel· Est.
Israeli cell‑therapy biotech developing off‑the‑shelf hESC‑derived treatments for ALS and diabetes.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Israeli cell‑therapy biotech developing off‑the‑shelf hESC‑derived treatments for ALS and diabetes.
DiabetesNeurodegenerative diseases
Technology Platform
A patented human embryonic stem‑cell platform that differentiates pluripotent cells into GMP‑grade, off‑the‑shelf therapeutic progenitors for neuroprotective and endocrine applications.
Opportunities
Scalable off‑the‑shelf cell therapies address large unmet needs in ALS and diabetes, with potential expansion to other neurodegenerative and metabolic diseases.
Risk Factors
Manufacturing scale‑up, regulatory hurdles for hESC‑derived products, and competition from other cell‑therapy developers could impede commercialization.
Competitive Landscape
Competes with firms like ViaCyte and Asterias, differentiating through its off‑the‑shelf, GMP‑grade differentiated cell approach and integrated gene‑editing capabilities.